Uterine cervix carcinoma in situ

This phase 1 trial tests a DNA vaccine designed to target HPV16, a virus that can cause high-grade cervical lesions (CIN2/3). The vaccine is given by injection into the muscle followed by a mild electrical pulse to help cells take up the DNA. The study includes both HIV-negative …

This phase II trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) can treat high-grade cervical precancer (CIN 2/3 or carcinoma in situ). The study will enroll 25 women and measure how many have a complete response at 6 months. The goal is to see if this drug…

This study investigates whether urine samples can be used to screen for cervical cancer in women living with HIV. Researchers will compare the accuracy of urine HPV testing with self-collected and provider-collected samples to detect cervical precancer (CIN2 or worse). The goal i…

This study follows 300 women aged 18–40 with severe cervical precancer (CIN 2 or 3) to see how often these lesions regress on their own or after surgery. Researchers will track HPV and Pap test results to identify factors that predict healing. The goal is to create a model that h…

This study will collect blood and tumor samples from 1,100 people with various cancers, including head and neck, ovarian, cervical, lung, and brain cancers. Researchers want to learn how immune cells called T cells behave in these tumors. The goal is to better understand why some…